Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.